Zacks.com on MSN4d
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in FocusXenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks ...
Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...
Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch - First of three planned Phase 3 azetukalner MDD studies underwa ...
Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch– First ...
Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...
While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and ...
With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback